CEO Sanjay Shukla describes the science behind tRNA synthetase biology and how aTyr is leveraging it against inflammatory and fibrotic diseases, especially pulmonary disease. He sets up the phase 3 for Efzofitimod in pulmonary sarcoidosis, and also pending data in systemic sclerosis.
View all episodes
By BiotechTV
4.3
66 ratings
CEO Sanjay Shukla describes the science behind tRNA synthetase biology and how aTyr is leveraging it against inflammatory and fibrotic diseases, especially pulmonary disease. He sets up the phase 3 for Efzofitimod in pulmonary sarcoidosis, and also pending data in systemic sclerosis.
3,222 Listeners
1,910 Listeners
124 Listeners
324 Listeners
61 Listeners
9,957 Listeners
86 Listeners
34 Listeners
353 Listeners
19 Listeners
60 Listeners
512 Listeners
41 Listeners
0 Listeners
4 Listeners
2 Listeners
6 Listeners
48 Listeners